Changes in erosion count scores during denosumab therapy in patients with rheumatoid arthritis-Reference-Cited by-同舟云学术

Changes in erosion count scores during denosumab therapy in patients with rheumatoid arthritis

Published:2024-01-13 Issue:31 Volume: Page:39-42
ISSN:2949-2807
Container-title:Medical alphabet
language:
Short-container-title:Medicinskij alfavit

Author:

Kovalenko P. S.¹^ORCID,Dydykina I. S.¹^ORCID,Smirnov A. V.¹^ORCID,Nasonov E. L.¹^ORCID

Affiliation:

1. V.A. Nasonova Research Institute of Rheumatology

Abstract

Background. Rheumatoid factor (RF) and antibodies to cyclic citrullinated peptide (ACCP) are associated with the progression of joint erosions in RA. Currently, the efficacy of anti-osteoporotic therapy for the prevention of erosive arthritis is discussing.The aim of the study. To evaluate the effect of denosumab on the erosion score progression in patients with RA and OP, taking into account the activity of the disease and RF or ACCP positivity.Materials and methods. The study included 66 postmenopausal women with determined diagnosis of RA and OP. Non-erosive arthritis was in 23 (35 %) patients, erosive – in 21 (32 %), ankylosis of the joints was diagnosed in 22 (33 %) people. RF (+) was detected in 47 (72 %) people, ACCP (+) – in 48 (74 %) people. Denosumab 60 mg was injected subcutaneously once every 6 months (two injections). The duration of follow-up was 12 months. RA activity was assessed by the DAS 28 index. The erosion was calculated according to the Sharp / van der Heijde (SVH) method.Results. RA patients were divided into four groups: RF (+) and RF (–), ACCP (+) and ACCP (–), comparable in basic clinical features. At the same time, in the RF (+) group, the duration of RA, the frequency of ankylosis of the joints and the erosion count were initially higher compared to the RF (–). After 12 months of therapy, 7 (14.9 %) patients in the RF (+) group and 8 (16.7 %) patients in the ACCP (+) group the number of erosions has increased. There was no increase in the number of erosions in the RF (–) and ACCP (–) groups. In the analyzed groups, there were no changes in the erosion count depending on RA activity.Conclusions. An increase in the erosion score was found in the RF (+) and ACCP (+) groups despite the treatment with denosumab. In the RF (–) and ACCP (–) groups this indicator did not change. The inclusion of denosumab in the complex therapy of RA and OP is reasonable for prevention of OP and erosions progression in women with seronegative RA.

Publisher

Alfmed LLC

Reference21 articles.

1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016; 388 (10055): 2023–2038. DOI: 10.1016/s0140–6736(16)30173–8.

2. Nasonov EL, Nasonova VA, editors. Rheumatology: National guideline. Moscow: GEOTAR-Media; 2008. 290 p. (In Russ.)

3. Aletaha D, Alasti F, Smolen JS. Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity. Ann Rheum Dis 2013; 72: 875–80. DOI: 10.1136/annrheumdis-2012–201517.

4. Katchamart W, Koolvisoot A, Aromdee E et al. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis. Rheumatol Int 2015; 35: 1693–9. DOI: 10.1007/s00296–015–3271–8.

5. Ishiguro N, Tanaka Y, Yamanaka H et al. Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study. Rheumatology 2019; 58: 997–1005. DOI: 10.1093/rheumatology/key416.